SecBot SecBot
3 ·Filed Oct 30, 2026

ADIL

ADIAL PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed17d 22h ago SEC0001213900-26-114575
Form 3: initial insider ownership statement
Actionable Insight • Neutral

New CFO onboarding is routine; monitor for future Form 4 filings that would indicate insider buying or selling activity.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$3.89
T+0 close · Oct 30, 2026 · via day close
Latest settled
+4.11%
T+5 · $4.05
Vs SPY
+4.03%
α at T+5
Next horizon
T+20
in 14d
  1. T+0 · Nov 2 $3.89entry
  2. T+1 · 14d ago +6.68%α +6.38% · $4.15
  3. T+5 · 8d ago +4.11%α +4.03% · $4.05
  4. T+11 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vassiliki Economides filed a Form 3 initial statement of beneficial ownership upon becoming Chief Financial Officer of Adial Pharmaceuticals. The filing discloses a stock option grant for 307,814 shares at a $5.76 exercise price, vesting over four years. This is a routine insider onboarding filing with no material financial impact.

Key Facts

  • Vassiliki Economides appointed Chief Financial Officer of Adial Pharmaceuticals, Inc.
  • Filing is an initial statement of beneficial ownership (Form 3) under Section 16(a).
  • Economides holds a stock option to purchase 307,814 shares at $5.76 per share.
  • Option vests 25% on first anniversary of grant date (August 19, 2026), then 36 equal monthly installments.
  • Option expires on August 19, 2036.
  • Power of Attorney filed as Exhibit 24 authorizing Matt Davidson and Cary Claiborne to file Section 16 reports.

Financial Impact

Stock option for 307,814 shares at $5.76 strike price; no immediate cash transaction or dilution impact.

dilution

Risk Factors

  • No material risks identified; this is a standard insider reporting filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001213900-26-114575
Document: 0001213900-26-114575-index-headers.html0001213900-26-114575
Document: 0001213900-26-114575-index.html0001213900-26-114575
Document: 0001213900-26-114575.txt0001213900-26-114575

Track record

23 reports on ADIL

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +138.93% at T+60 after the Jun 11, 2026 report. 5 of 10 went positive at some point.

Filters
  1. Nov 12, 20265d ago Press Release Neutral 4/10 No price data
  2. Oct 30, 202617d ago 3 Neutral 2/10 Entry $3.89 settles Jan 29
  3. Oct 30, 202617d ago 3 Neutral 2/10 Viewing Entry $3.89 settles Jan 29
  4. Oct 28, 202620d ago 8-K Neutral 5/10 Entry $4.88 settles Jan 27
  5. Oct 28, 202620d ago Press Release Neutral 5/10 Entry $4.88 settles Jan 27
  6. Oct 27, 202621d ago EFFECT Bearish 6/10 Entry $3.71 settles Jan 25
  7. Oct 20, 202627d ago 10-Q/A Bearish 7/10 Entry $4.11 settles Jan 19
  8. Oct 20, 202627d ago S-3/A Bearish 7/10 Entry $4.11 settles Jan 19
  9. Oct 16, 20264w ago DEFA14A Bearish 5/10 Entry $3.62 settles Jan 14
  10. Oct 16, 20264w ago 8-K Bearish 5/10 Entry $3.62 settles Jan 14
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026